Characteristics | Patients with IM-SC LN recurrence (n = 14) | Patients with distant metastasis (n = 274) | P-value |
---|---|---|---|
Disease-free survival, month (mean ± SD) | 30.71 ± 6.87 | 33.25 ± 1.63 | 0.732 |
Age, years (mean ± SD) | 45.36 ± 3.892 | 52.5 ± 12.93 | 0.093 |
Menopausal status at primary surgery | |||
Pre- | 9 | 133 | 0.250 |
Post- | 5 | 141 | |
Clinical T stagea | |||
T1 | 3 | 44 | 0.615 |
T2 | 9 | 160 | |
T3 | 2 | 41 | |
T4 | 0 | 29 | |
Clinical N stagea | |||
0 | 6 | 121 | 0.732 |
1 | 6 | 102 | |
2 | 1 | 9 | |
3 | 1 | 42 | |
Clinical stagea | |||
I | 2 | 32 | 0.311 |
II | 10 | 149 | |
III | 2 | 93 | |
Perioperative chemotherapy | |||
No | 4 | 52 | 0.376 |
Yes | 10 | 222 | |
Surgical procedure of the primary tumor | |||
Partial mastectomy | 4 | 79 | 0.983 |
Mastectomy | 10 | 195 | |
Pathological LN status of the primary tumor | |||
Negative | 7 | 87 | 0.156 |
Positive | 7 | 187 | |
LI status of the primary tumor | |||
Negative | 6 | 87 | 0.260 |
Positive | 8 | 187 | |
ER status | |||
Positive | 5 | 168 | 0.152 |
Negative | 9 | 105 | |
HER2 status | |||
Positive | 5 | 35 | 0.111 |
Negative | 9 | 238 |